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Background: The optimal technique for performing lung IMRT remains poorly defined. 
We hypothesize that improved dose distributions associated with normal tissue-sparing 
IMRT can allow safe dose escalation resulting in decreased acute and late toxicity.
Methods: We performed a retrospective analysis of 82 consecutive lung cancer patients 
treated with curative intent from 1/10 to 9/14. From 1/10 to 4/12, 44 patients were 
treated with the community standard of three-dimensional conformal radiotherapy or IMRT 
without specific esophagus or contralateral lung constraints (standard RT). From 5/12 
to 9/14, 38 patients were treated with normal tissue-sparing IMRT with selective sparing 
of contralateral lung and esophagus. The study endpoints were dosimetry, toxicity, and 
overall survival.
results: Despite higher mean prescribed radiation doses in the normal tissue-sparing 
IMRT cohort (64.5 vs. 60.8 Gy, p = 0.04), patients treated with normal tissue-sparing 
IMRT had significantly lower lung V20, V10, V5, mean lung, esophageal V60, and 
mean esophagus doses compared to patients treated with standard RT (p ≤ 0.001). 
Patients in the normal tissue-sparing IMRT group had reduced acute grade ≥3 
esophagitis (0 vs. 11%, p < 0.001), acute grade ≥2 weight loss (2 vs. 16%, p = 0.04), 
and late grade ≥2 pneumonitis (7 vs. 21%, p = 0.02). The 2-year overall survival 
was 52% with normal tissue-sparing IMRT arm compared to 28% for standard RT 
(p = 0.015).
conclusion: These data provide proof of principle that suboptimal radiation dose distri-
butions are associated with significant acute and late lung and esophageal toxicity that 
may result in hospitalization or even premature mortality. Strict attention to contralateral 
lung and esophageal dose–volume constraints are feasible in the community hospital 
setting without sacrificing disease control.
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introduction
Lung cancer remains the most common cause of cancer mortality 
in the United States with the majority of patients presenting with 
locally advanced or metastatic disease (1). Patients with locally 
advanced and oligometastatic lung cancer are commonly treated 
with chemoradiation with curative intent (2–4). Lung cancer treat-
ment planning has significantly evolved over the past two decades 
(2, 5). RTOG 94-10 used three-dimensional conformal radio-
therapy limiting the spinal cord to ≤48 Gy without specific lung or 
esophageal constraints (2). In the concurrent chemoradiation arm 
of RTOG 94-10, 23% of patients developed grade ≥3 esophagitis 
and 13% of patients developed grade ≥3 pulmonary toxicity (2). 
As the clinical significance of volume of lung receiving 20 Gy and 
mean lung dose became established, intensity-modulated radiation 
therapy emerged as a potential approach to reduce lung toxicity (6, 
7). In RTOG 0617, either IMRT or three-dimensional conformal 
radiotherapy was allowed. RTOG 0617 strongly recommended a 
mean lung dose ≤20 Gy, volume of lung receiving 20 Gy ≤37%, 
and a mean esophagus dose of <34  Gy (5). Despite expanded 
use of normal tissue constraints, 20% of patients in RTOG 0617 
developed grade ≥3 pulmonary toxicity. In RTOG 0617, 7% of 
patients receiving 60 Gy and concurrent chemotherapy developed 
grade ≥3 esophagitis, while 21% of patients receiving 74 Gy and 
concurrent chemotherapy developed grade ≥3 esophagitis (5). 
Maximum grade of esophagitis predicted survival on multivariate 
analysis (5). Taken together, these data suggest that IMRT tech-
nique for locally advanced lung cancer requires further refinement, 
particularly in the community oncology setting.
Although esophageal sparing was not highly prioritized in the 
past, there are emerging data linking weight loss and survival in 
patients with lung cancer treated with chemoradiation (8). A recent 
analysis linked volume of esophagus receiving 60 Gy with esopha-
geal toxicity (9). The MD Anderson group has demonstrated the 
clinical significance of sparing the contralateral lung by limiting 
volumes of lung receiving 5 and 10  Gy (10). We investigated 
whether IMRT designed to limit lung V20, V10, V5, mean lung 
dose, and esophageal dose could reduce the risk of treatment 
toxicity compared to historical controls treated with usual care.
Materials and Methods
Patient selection
This retrospective study was approved by the Institutional Review 
Board. We reviewed 82 consecutive patients with stage II–III 
lung cancer, and patients with stage IV lung cancer with solitary 
oligometastases treated from January 2010 to September 2014. 
All patients had laboratory studies, computed tomography of the 
chest, and pathologic confirmation of malignancy. All patients had 
a complete metastatic workup with the vast majority of patients 
staged with whole body positron emission tomography and CT or 
MRI of the head. All patients were treated with potentially curative 
doses of ≥50 Gy for definitive radiation or ≥45 Gy in combination 
with surgery. Since the primary endpoints were dosimetry and 
toxicity rather than survival, no attempt was made to exclude 
patients based on histology or adjunctive treatment modalities 
(surgery, chemotherapy).
standard radiation Technique
From January 2010 to April 2012, patients were treated by four 
highly experienced radiation oncologists using standard planning 
techniques. The most common technique was three-dimensional 
conformal radiotherapy alone (55%) although IMRT alone (24%) 
or in combination with 3D-CRT (21%) was also used. When IMRT 
was utilized, a median of five fields were used, with 33% of patients 
treated with seven to nine IMRT fields. During this period, the 
spinal cord was limited to a maximum dose of 50 Gy, the lung V20 
was generally limited to ≤37%, and mean lung dose was ≤20 Gy. 
Patients were treated on a Varian 21C/D linear accelerator with 
CT-based planning with Pinnacle using tissue inhomogeneity cor-
rections (Philips Medical Systems, Andover, MA, USA). Patients 
were immobilized in the supine position using a custom Alpha 
Cradle mold (Alpha Cradle Molds, Akron, OH, USA). Patients 
treated during this interval were classified as standard RT.
normal Tissue-sparing iMrT Technique
From May 2012 to September 2014, all patients were treated by 
a single high volume radiation oncologist (J.K.) with normal 
tissue-sparing IMRT. A minimum of 50 Gy was prescribed for 
small cell carcinoma and a minimum of 60 Gy was prescribed for 
non-small cell lung cancer. Further dose escalation was pursued 
only when dose constraints were not exceeded (Table  1). The 
most common technique used was IMRT alone (75%), usually a 
four-field technique. Patients with very bulky disease were treated 
with combined 3D-CRT (generally AP/PA or shallow obliques) in 
combination with IMRT (20%). Two patients (5%) with bilateral 
lung and/or hilar involvement, but no mediastinal involvement 
on PET, were treated with bilateral AP–PA fields as the optimal 
approach to lung and esophageal sparing.
A median of 4 IMRT fields were used with 98% of patients 
treated with ≤5 fields. From May 2012 through January 2014, 
patients were treated on a Varian 21C/D with CT-based planning 
with PET/CT fusion. The gross tumor volume was defined as the 
primary tumor or any regional lymph nodes on CT (>1 cm on short 
axis) or PET. Fusion of inhalation, expiration, and free breathing 
CT scans were used to assess respiratory motion and to create 
an ITV. After February 2014, patients were treated on the Varian 
TrueBeam with 4-D CT simulation using Eclipse planning. ITV to 
CTV margins were 0.5–1.0 cm. CTV to PTV margins of 0.5–1 cm 
were used to create a PTV. In general, smaller margins within the 
range were used for bulky disease or tumor adherent to bone. 
When there was PET-positive disease involving the esophagus or 
TaBle 1 | normal organ constraints used for normal tissue-sparing iMrT 
lung plans after May 2012.
lungs esophagus spinal cord heart Brachial 
plexus
Dmean 
<20 Gy
Mean <34 Gy Dmax <45 Gy D60 <33% Dmax <66 Gy
V20 <37% Dmax <100% Rx 
(when feasible)
Spinal canal +  
5 mm <50 Gy
D45 <66%
V10 <50% D40 <100%
V5 <65%
TaBle 2 | Patient characteristics for patients treated with standard rT or 
esophagus and contralateral lung-sparing iMrT.
normal tissue-sparing 
iMrT (n = 44)
standard 
(n = 38)
p
age (years)
Median 72 67 0.63
Range 30–87 48–83
gender
Male 25 (56%) 17 (45%) 0.28
Female 19 (44%) 21 (55%)
histology
Adenocarcinoma 18 (41%) 14 (37%) 0.29
Squamous cell carcinoma 15 (34%) 12 (32%)
Small cell carcinoma 7 (16%) 10 (26%)
Non-small cell lung 
cancer, NOS
4 (9%) 2 (5%)
smoking (pack years)
Never 3 (7%) 1 (3%) 0.38
1–20 5 (11%) 13 (34%)
21–40 14 (37%) 5 (13%)
>40 22 (50%) 18 (47%)
race
White 39 (89%) 29 (76%) 0.15
Non-white 5 (11%) 9 (24%)
clinical stage
II 7 (16%) 4 (11%) 0.64
IIIA 14 (32%) 19 (50%)
IIIB 16 (36%) 11 (29%)
IV 7 (16%) 4 (11%)
recurrent
No 37 (84%) 34 (89%) 0.48
Yes 7 (16%) 4 (11%)
ecOg performance status
0–1 27 (61%) 30 (79%) 0.12
2 12 (27%) 5 (13%)
3 5 (11%) 3 (8%)
Weight loss
<10% 39 (89%) 34 (89%) 0.70
>10% 5 (11%) 4 (11%)
location
Right upper 16 (36%) 10 (26%) 0.10 
(upper vs. 
lower)
Right middle 5 (11%) 3 (8%)
Right lower 9 (20%) 3 (8%)
Left upper 9 (20%) 16 (42%)
Left lower 4 (9%) 5 (13%)
Lymph node only 1 (2%) 1 (3%)
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vertebral bodies, the expanded PTV volumes were trimmed off 
critical structures to meet esophagus and spinal cord constraints.
A typical patient in the normal tissue-sparing IMRT group with 
a primary lung tumor with ipsilateral hilar, paratracheal, and/or 
aortopulmonary lymph nodes was usually treated to 64–70 Gy. 
When a final boost was utilized, the margins from GTV to boost 
PTV were limited to 1–1.2 cm in the superior inferior direction, 
0.8–1.0  cm in the anterior posterior direction, and 0.5–0.8  cm 
in the medial lateral direction. Simultaneous integrated boost 
planning was performed to deliver radiation dose above 60 Gy to 
the bulky primary tumor and lymph nodes while administering a 
more conservative dose of 59.4–63 Gy to small volume CT or PET 
positive mediastinal lymph nodes measuring <2 cm that were in 
close proximity to the esophagus. For patients with contralateral 
mediastinal or hilar adenopathy, dose escalation beyond 60 Gy was 
usually not technically feasible. Although elective nodal irradiation 
was not performed, all PET positive lymph nodes and lymph nodes 
measuring >1 cm on short axis on CT were targeted for treatment.
Follow-Up
Patients were assessed weekly during radiation for toxicity, and 
weight was recorded. Following treatment, patients were reassessed at 
1 month. Clinical follow-up, CT, and/or PET were performed at 3- to 
4-month intervals for 2 years and at 4- to 6-month intervals thereafter. 
Patients were censored at last follow-up or death. Date of death was 
confirmed using the social security death index. Hospitalization was 
confirmed by reviewing the electronic medical record (EPIC).
Toxicity scoring and statistical Methods
Treatment-related toxicity was scored using the Common 
Terminology Criteria for Adverse Events version 4.0. Statistical 
analyses were performed on the entire cohort and for the pre-
determined subset of patients with stage II–III non-small cell 
lung cancer who were treated with definitive chemoradiation. 
Hospitalizations following treatment were documented in the 
EPIC electronic medical record. Differences in toxicity rates were 
assessed using a two-sided chi-square test with p values of <0.05 
considered statistically significant. Local recurrence was defined 
as radiographic progression within the radiation volume that 
was not attributed to radiation fibrosis or pneumonitis. Actuarial 
locoregional control and overall survival were calculated using the 
Kaplan–Meier method from the initiation of radiation therapy.
results
Patients and Tumor characteristics
Table 2 summarizes the patient and tumor characteristics for the 38 
patients treated with standard technique between 1/10 and 4/12 and 
the 44 patients treated with normal tissue-sparing IMRT between 
5/12 and 9/14. Median follow-up time was 14  months (range 
1.4–35.3 months). Both groups were well matched in terms of age, 
gender, histology, smoking history, race, clinical stage, performance 
status, pre-treatment weight loss, tumor location, and GTV volume. 
The median age for all patients was 69 with 53% male, 79% non-small 
small cell, 83% white, 70% ECOG 0-1, and 73% stage III. The mean 
GTV volume for patients receiving standard RT was 176.8 (range 
13–615 cc) vs. 155.6 (range 4–803 cc) for IMRT patients (p = 0.52).
Treatment characteristics
Table  3 summarizes treatment parameters. Most patients were 
treated with concurrent chemotherapy (87%) and without surgery 
(93%). Patients in the normal tissue-sparing IMRT group received 
a higher mean radiation (64.5  Gy ±  SD 5.0 vs. 60.8  Gy ±  6.2, 
p = 0.04) and were significantly more likely to receive IMRT only 
compared to the standard group (75 vs. 24%, p < 0.001).
The normal tissue-sparing IMRT cohort had significantly lower 
lung V20, V10, V5, mean lung, maximum esophagus, and mean 
esophagus doses (p ≤ 0.001). Mean lung V20 was 23.3 Gy ± SD 
7.2 in the normal tissue-sparing IMRT group vs. 32.2 Gy ± SD 
11.6 for standard RT. Mean esophagus dose was 20.8 Gy ± SD 
10.9 with normal tissue-sparing IMRT vs. 34.0  Gy ±  SD 13.7 
TaBle 3 | Treatment characteristics for patients treated with standard rT 
or esophagus and contralateral lung-sparing iMrT.
normal  
tissue-sparing  
iMrT (n = 44)
standard  
(n = 38)
p
radiation dose
Median 66 63 0.04
<59.4 Gy 6 (14%) 9 (24%)
59.4–63 Gy 11 (25%) 16 (32%)
63.1–66 Gy 11 (25%) 5 (13%)
>66.1 Gy 16 (36%) 8 (21%)
Technique
IMRT only 33 (75%) 9 (24%) <0.001
Combined 
3D-CRT + IMRT
9 (20%) 8 (21%)
3D-CRT only 2 (5%) 21 (55%)
number of iMrT fields
Median 4 5 0.001
Range 3–7 4–9
Treatment time
Median 49 53 0.31
Range 37–68 29–180
chemotherapy
Yes 36 (82%) 35 (92%) 0.07
No 8 (18%) 3 (8%)
surgery
Yes 4 (9%) 2 (5%) 0.51
No 40 (91%) 36 (95%)
lung volume 
receiving 20 gy
23.3% (SD ± 7.2) 32.2% 
(SD ± 11.6)
<0.001
Range 7–38% 10–58%
lung volume 
receiving 10 gy
33.5% (SD ± 10.0) 45.7% 
(SD ± 15.4)
<0.001
Range 14–52% 15–79%
lung volume 
receiving 5 gy
44.5% (SD ± 13.4) 61.2% 
(SD ± 18.9)
<0.001
Range 16–80% 19–99%
Mean lung dose 14.0 Gy 
(SD ± 5.5 Gy)
17.6 Gy 
(SD ± 5.6 Gy)
0.005
Range 5.8–39.9 Gy 5.9–26.2 Gy
Maximum esophagus 
dose
56.5 
(SD ± 13.6 Gy)
61.1 
(SD ± 14.0 Gy)
0.07
Range 6–68.3 Gy 45.8–70.0 Gy
Mean esophagus 
dose
20.8 Gy 
(SD ± 10.9 Gy)
34.0 Gy 
(SD ± 13.7 Gy)
<0.001
Range 0.9–45.3 Gy 6.8–60.1 Gy
esophageal volume 
receiving 60 gy
3.5 (SD ± 5.8 Gy) 14.5 
(SD ± 16.4 Gy)
0.001
Range 0–19.0 Gy 0–58.0 Gy
Mean heart dose 15.2 Gy 
(SD ± 10.4 Gy)
18.6 Gy 
(SD ± 9.8 Gy)
0.14
Range 0.7–39.1 Gy 0.7–34.3 Gy
Maximum spinal cord 
dose
36.2 
(SD ± 11.6 Gy)
42.1 
(SD ± 9.3 Gy)
0.013
Range 2.1–46.5 Gy 4.9–49.5 Gy
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for standard RT (p = 0.001). Representative dose distributions 
for standard RT and normal tissue-sparing IMRT are shown in 
Figures 1 and 2.
FigUre 1 | Dose distribution for a representative patient with a 2.5 cm 
T3n0M0 stage iiB right lower lobe adenocarcinoma treated with 
standard rT technique. The patient was treated with carboplatin, 
paclitaxel, and thoracic RT to 63 Gy via six-field IMRT followed by an 
eight-field IMRT boost. The patient developed acute grade 2 dysphagia and 
grade 1 dyspnea and died 8 months after treatment from acute myocardial 
infarction without evidence of progression. (a) Axial dose distribution 
demonstrates high target volume conformality but inclusion of a significant 
volume of esophagus within the high dose–volume. A significant volume of 
lung received at least 5 Gy. (B) Coronal dose distribution. (c) Dose–volume 
histogram demonstrates high-esophageal V60 and high lung V5, V10, V20, 
and mean lung doses.
acute and late Toxicity
The reduction in esophageal doses with normal tissue-sparing 
IMRT translated to significantly reduced incidence of acute grade 
≥2 esophagitis (71 vs. 31%, p < 0.001). The incidence of acute 
grade ≥3 esophagitis was 0% with normal tissue-sparing IMRT 
compared to 11% with standard RT (p < 0.001). Average weight loss 
was 10.8 pounds ± SD 10.0 for standard RT vs. 4.8 pounds ± SD 
5.6 for normal tissue-sparing IMRT (p = 0.003). Normal tissue-
sparing IMRT reduced the risk of grade ≥2 weight loss (16 vs. 2%, 
p = 0.04). There were no significant differences in acute fatigue, 
nausea, lung, heart, or skin toxicity between treatment groups, 
and grade 3 toxicities were uncommon (<5%).
There was a significant reduction in grade ≥2 radiation pneumo-
nitis with normal tissue-sparing IMRT (21 vs. 7%, p = 0.02). Three 
patients in the standard RT group-developed grade 5 pneumonitis 
had lung V20 values of 41, 48, and 58% and lung V5 values of 90, 
99, and 88%, respectively. There was also one case of late grade 3 
esophagitis and two cases of grade 3 pneumonitis with standard 
RT vs. none for normal tissue-sparing IMRT. The incidence of late 
grade ≥3 pulmonary toxicity was 0% with normal tissue-sparing 
IMRT compared to 14% with standard RT (p = 0.02). The incidence 
of hospitalization for dehydration and/or pulmonary symptoms 
within 6 months of treatment was 11% for normal tissue-sparing 
IMRT patients vs. 37% for standard RT (p = 0.008).
survival
The 2-year overall survival was 52% with normal tissue-sparing 
IMRT vs. 28% for standard RT (p = 0.015). The median survival for 
normal tissue IMRT was >31 months vs. 13 months for standard 
RT (Figure 3A). The 2-year locoregional control was 70% with 
normal tissue-sparing IMRT vs. 42% for standard RT (p = 0.12).
Patients with stage ii–iii non-small cell lung 
cancer Treated with Definitive chemoradiation
A total of 43 patients had stage II–IIIB non-small cell lung cancer 
that was treated with definitive chemoradiation. The patients 
treated with normal tissue-sparing IMRT were more likely to 
receive IMRT, were treated with fewer IMRT fields, and had signifi-
cant reductions in lung V20, V10, V5, mean lung dose, maximum 
esophagus dose, mean esophagus dose, and maximum spinal cord 
doses. Patients treated with normal tissue-sparing IMRT had 
reduced rates of acute ≥2 esophagitis (81 vs. 35%, p = 0.001), lower 
median weight loss (12.8 vs. 5.4 pounds, p = 0.01) and decreased 
late ≥2 radiation pneumonitis (19 vs. 0%, p = 0.04). There was 
a trend toward decreased hospitalization for dehydration and/or 
pulmonary symptoms within 6 months of treatment with normal 
tissue-sparing IMRT (33 vs. 12%, p = 0.12). The 2-year overall 
survival was 57% with normal tissue-sparing IMRT vs. 20% for 
standard RT (p = 0.02). The median survival for normal tissue 
IMRT was >31 vs. 16 months for standard RT (Figure 3B).
Discussion
IMRT has been previously shown to reduce radiation dose to 
normal lung translating to reduced pulmonary toxicity for patients 
with locally advanced lung cancer (11). Although IMRT is increas-
ingly used in locally advanced lung cancer, a clinical advantage 
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over three-dimensional conformal radiotherapy remains unclear in 
population-based studies (12). The recently published RTOG 0617 
trial allowed for IMRT for locally advanced lung cancer but a benefit 
for IMRT was not observed (5). As a result, some payers are reluc-
tant to endorse IMRT for lung cancer (13). Skeptics have started to 
question the continuing focus on improving dose distributions in 
radiation oncology research (14). In terms of process improvements, 
expanded use of dose–volume constraints to improve outcome for 
patients requiring highly complex radiation treatment plans for 
locally advanced lung cancer could be considered analogous to use 
of checklists in other domains of medicine (15).
In the absence of randomized trials comparing normal tissue 
IMRT vs. standard RT, our study represents a natural experiment 
where lung cancer treatment technique abruptly transitioned 
from standard RT performed by four board-certified radiation 
oncologists to a single high volume radiation oncologist who 
implemented lung and esophagus-sparing IMRT (16). This study 
suggests that improved dose distributions resulting from adopting 
a policy of normal tissue-sparing IMRT favorably impacts outcome 
in lung cancer patients, including locally advanced non-small cell 
lung cancer compared to usual care by reducing high-grade lung 
and esophageal toxicity. The observed improvement in dosimetric 
for standard RT (p = 0.001). Representative dose distributions 
for standard RT and normal tissue-sparing IMRT are shown in 
Figures 1 and 2.
FigUre 1 | Dose distribution for a representative patient with a 2.5 cm 
T3n0M0 stage iiB right lower lobe adenocarcinoma treated with 
standard rT technique. The patient was treated with carboplatin, 
paclitaxel, and thoracic RT to 63 Gy via six-field IMRT followed by an 
eight-field IMRT boost. The patient developed acute grade 2 dysphagia and 
grade 1 dyspnea and died 8 months after treatment from acute myocardial 
infarction without evidence of progression. (a) Axial dose distribution 
demonstrates high target volume conformality but inclusion of a significant 
volume of esophagus within the high dose–volume. A significant volume of 
lung received at least 5 Gy. (B) Coronal dose distribution. (c) Dose–volume 
histogram demonstrates high-esophageal V60 and high lung V5, V10, V20, 
and mean lung doses.
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endpoints translated into a clinically significant reduction in 
hospitalization for dehydration and pulmonary complications 
without sacrificing disease control. Patients treated with normal 
tissue-sparing IMRT had improved survival compared to patients 
treated with standard RT. Importantly, normal tissue-sparing 
IMRT could be safely performed with resources available within 
a community hospital cancer center.
The target volumes, organs at risk, and planning techniques for 
locally advanced lung cancers are diverse depending on location 
and size of the primary tumor and extent of lymph node involve-
ment. Although there is not yet universal agreement on the clinical 
relevance of lung V10 and V5, the negative impact of bilateral 
low-dose (<15  Gy) lung irradiation has been documented in 
diverse conditions including mesothelioma, total lung irradiation 
for Wilm’s tumor, and total body irradiation for hematologic malig-
nancies (17–19). The heterogeneity of IMRT planning approaches 
is reflected by published IMRT lung plans using between four 
and nine fields (20, 21). Typical IMRT plans utilize five or more 
coplanar beams that can result in up to 98% of the lung receiving 
5 Gy for patients with large PTV volumes (7). Using five beams 
has been associated with reduced lung V5 compared to plans using 
seven or nine beams (22). Recently, five- to six-field IMRT plan 
was associated with a higher rate of grade ≥3 radiation esophagitis 
than three-dimensional conformal radiotherapy (23).
FigUre 2 | Dose distribution for a representative patient with a 6.6 cm 
T4n2M0 stage iiiB right upper lobe adenocarcinoma treated with 
contralateral lung and esophageal sparing iMrT technique. The patient 
was treated with carboplatin, paclitaxel, and thoracic RT to 73 Gy via four-field 
IMRT. The patient developed acute grade 2 dysphagia, grade 1 dermatitis, and 
right upper arm deep vein thrombosis. The patient remains alive and free of 
progression or late toxicity at 21 months. (a) Axial dose distribution 
demonstrates relatively poor conformality but excellent sparing of the 
esophagus and contralateral lung. (B) Coronal isodose distribution.  
(c) Dose–volume histogram demonstrates excellent coverage of the dominant 
mass (PTV70) and targeted lymph nodes (PTV63) with selective sparing of 
esophagus and lung.
FigUre 3 | (a) Overall survival for lung cancer patients treated with 
esophagus and normal lung-sparing IMRT vs. standard technique. (B) Overall 
survival for patients with stage II–IIIB non-small cell lung cancer receiving 
definitive chemoradiation treated with esophagus and normal lung-sparing 
IMRT vs. standard technique.
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Since radiation pneumonitis is a potentially fatal complication, 
limiting contralateral lung exposure makes intuitive sense but is 
technically challenging (6). It is generally our preference to sacri-
fice conformality for contralateral lung avoidance by using four- to 
five-beam IMRT for the majority of patients. In cases where extent 
of disease could not be adequately covered by four- to five-IMRT 
fields, our preference has been to utilize limited field 3D-CRT (AP/
PA or shallow obliques) for at least part of the treatment (24, 25).
Esophageal sparing is controversial because mediastinal lymph 
nodes, especially subcarinal, posterior paratracheal, and parae-
sophageal lymph nodes, often overlap with the esophagus. In this 
study, esophageal sparing was accomplished by simply avoiding 
the esophagus when there was no subcarinal or paraesophageal 
adenopathy on PET/CT. When subcarinal or paraesophageal 
lymph nodes were involved, these regions were not treated above 
60 Gy by constraining esophageal V60 below prescription dose.
A central conundrum in lung cancer radiotherapy is that 60 Gy 
with concurrent chemotherapy is logically inadequate for bulky 
disease but efforts to further escalate treatment intensity using 
standard radiation techniques have been unsuccessful. RTOG 
0617 implies that dose escalation above 60 Gy with concurrent 
chemotherapy is counterproductive due to increased toxicity 
(26). A prior CALGB trial using 66 Gy with concurrent chemo-
therapy ± induction chemotherapy resulted in poor outcomes in 
the cooperative group setting with survival (27). The notion that 
radiation dose intensification beyond 60 Gy in 6 weeks, a regimen 
established by RTOG 73-01, cannot be safely performed the era of 
IMRT, IGRT, and four-dimensional computed tomography simula-
tion is counterintuitive (11, 28). Locoregional failure occurred in 
31% of patients receiving 60 Gy and concurrent chemotherapy 
in RTOG 0617 (26). A potential solution explored in this study 
is administering the standard RTOG 0617 dose of 60 Gy to all 
areas of suspected involvement but selectively boosting bulky 
primary tumor and lymph nodes to 64–70 Gy. In this study, 61% 
of patients in the normal tissue-sparing IMRT cohort were treated 
to 64–70 Gy suggesting that selective dose escalation above 60 Gy 
can safely be performed in appropriately selected patients when 
using strict dose–volume constraints. Stereotactic radiotherapy 
boost represents a similar concept but remains experimental (29).
The authors acknowledge significant weaknesses inherent in 
a retrospective single-institution study based in a 437-bed com-
munity teaching hospital. The sample size was small and there 
was significant heterogeneity of the patient population in terms 
of stage, histology, treatment modality, and treatment technique. 
When stratifying results by stage (II–III vs. IV), histology (non-
small cell vs. small cell), and treatment modality (chemoradiation 
vs. radiation alone), significant reductions in lung and esophageal 
dosimetry, esophagitis, weight loss, and radiation pneumonitis 
remained statistically significant. Small cell lung cancers were 
included because they were treated with radiation doses and 
volumes similar to non-small cell lung cancers. The survival in 
the standard RT arm was similar to results published in CALGB 
39801, which is worse than expected for a modern cohort (27). 
Additionally, this study did not specifically evaluate whether 
the observed benefit was due to IMRT, four-dimensional CT 
simulation, PET/CT fusion, higher radiation dose, or physician 
experience but instead represented two cohorts separated in time 
and treated by different physicians with different normal tissue 
constraints. Despite these limitations, this study highlights the 
potential importance of technique in lung cancer radiotherapy in 
a real-world setting.
In conclusion, these hypothesis-generating data suggest that 
suboptimal radiation dose distributions associated with stand-
ard technique may result in significant acute and late lung and 
esophageal toxicity that result in hospitalization or even premature 
mortality. We suggest a relatively simple four-field IMRT tech-
nique with strict attention to contralateral lung and esophageal 
dose– volume constraints for further validation as a potential class 
solution for many locally advanced lung cancers.
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